

Title (en)

GENE SEQUENCE VARIATIONS WITH UTILITY IN DETERMINING THE TREATMENT OF DISEASE

Title (de)

GENSEQUENZ-VARIATIONEN NÜTZLICH FÜR DIE BESTIMMUNG DER BEHANDLUNGSMETHODE BEI KRANKHEITEN

Title (fr)

VARIATIONS DE SEQUENCES GENIQUES PRESENTANT UNE UTILITE POUR LA SELECTION DU TRAITEMENT D'UNE MALADIE

Publication

EP 1224322 A2 20020724 (EN)

Application

EP 00919254 A 20000120

Priority

- US 0001392 W 20000120
- US 12104799 P 19990222
- US 13944099 P 19990615
- US 35774399 A 19990720

Abstract (en)

[origin: WO0050639A2] The present disclosure describes the use of genetic variance information for genes involved in gene pathways in the selection of effective methods of treatment of a disease or condition. The variance information is indicative of the expected response of a patient to a method of treatment. Methods of determining relevant variance information and additional methods of using such variance information are also described.

IPC 1-7

C12Q 1/68

IPC 8 full level

C12N 15/09 (2006.01); **A61K 45/00** (2006.01); **A61P 1/00** (2006.01); **A61P 1/16** (2006.01); **A61P 3/04** (2006.01); **A61P 3/10** (2006.01); **A61P 5/00** (2006.01); **A61P 5/14** (2006.01); **A61P 5/18** (2006.01); **A61P 5/38** (2006.01); **A61P 7/00** (2006.01); **A61P 7/06** (2006.01); **A61P 9/00** (2006.01); **A61P 9/04** (2006.01); **A61P 9/06** (2006.01); **A61P 9/08** (2006.01); **A61P 9/10** (2006.01); **A61P 9/12** (2006.01); **A61P 11/00** (2006.01); **A61P 11/06** (2006.01); **A61P 13/02** (2006.01); **A61P 13/12** (2006.01); **A61P 15/00** (2006.01); **A61P 15/16** (2006.01); **A61P 15/18** (2006.01); **A61P 17/00** (2006.01); **A61P 17/06** (2006.01); **A61P 17/10** (2006.01); **A61P 17/14** (2006.01); **A61P 19/00** (2006.01); **A61P 19/02** (2006.01); **A61P 19/10** (2006.01); **A61P 21/00** (2006.01); **A61P 25/00** (2006.01); **A61P 25/04** (2006.01); **A61P 25/06** (2006.01); **A61P 25/08** (2006.01); **A61P 25/14** (2006.01); **A61P 25/16** (2006.01); **A61P 25/18** (2006.01); **A61P 25/22** (2006.01); **A61P 25/24** (2006.01); **A61P 25/28** (2006.01); **A61P 29/00** (2006.01); **A61P 35/00** (2006.01); **A61P 37/02** (2006.01); **C12Q 1/02** (2006.01); **C12Q 1/68** (2006.01)

CPC (source: EP)

A61P 1/00 (2017.12); **A61P 1/16** (2017.12); **A61P 3/04** (2017.12); **A61P 3/10** (2017.12); **A61P 5/00** (2017.12); **A61P 5/14** (2017.12); **A61P 5/18** (2017.12); **A61P 5/38** (2017.12); **A61P 7/00** (2017.12); **A61P 7/06** (2017.12); **A61P 9/00** (2017.12); **A61P 9/04** (2017.12); **A61P 9/06** (2017.12); **A61P 9/08** (2017.12); **A61P 9/10** (2017.12); **A61P 9/12** (2017.12); **A61P 11/00** (2017.12); **A61P 11/06** (2017.12); **A61P 13/02** (2017.12); **A61P 13/12** (2017.12); **A61P 15/00** (2017.12); **A61P 15/16** (2017.12); **A61P 15/18** (2017.12); **A61P 17/00** (2017.12); **A61P 17/06** (2017.12); **A61P 17/10** (2017.12); **A61P 17/14** (2017.12); **A61P 19/00** (2017.12); **A61P 19/02** (2017.12); **A61P 19/10** (2017.12); **A61P 21/00** (2017.12); **A61P 25/00** (2017.12); **A61P 25/04** (2017.12); **A61P 25/06** (2017.12); **A61P 25/08** (2017.12); **A61P 25/14** (2017.12); **A61P 25/16** (2017.12); **A61P 25/18** (2017.12); **A61P 25/22** (2017.12); **A61P 25/24** (2017.12); **A61P 25/28** (2017.12); **A61P 29/00** (2017.12); **A61P 35/00** (2017.12); **A61P 37/02** (2017.12); **C12Q 1/6883** (2013.01); **C12Q 2600/106** (2013.01); **C12Q 2600/136** (2013.01); **C12Q 2600/142** (2013.01); **C12Q 2600/156** (2013.01); **C12Q 2600/158** (2013.01); **C12Q 2600/172** (2013.01); **Y02A 90/10** (2017.12)

Citation (search report)

See references of WO 0050639A2

Citation (examination)

- TONSTAD ET AL: "The C677T mutation in the methylenetetrahydrofolate reductase gene predisposes to hyperhomocysteinemia in children with familial hypercholesterolemia treated with cholestyramine", JOURNAL OF PEDIATRICS, vol. 132, no. 2, February 1998 (1998-02-01), MOSBY-YEAR BOOK, ST. LOUIS, MO, US, pages 365 - 368, XP005692954
- NELEN ET AL: "Methylenetetrahydrofolate reductase polymorphism affects the change in homocysteine and folate concentrations resulting from low dose folic acid supplementation in women with unexplained recurrent miscarriages", J OF NUTRITION, vol. 128, no. 8, August 1998 (1998-08-01), pages 1336 - 1341
- DELOUGHIER ET AL: "Common mutation in methylenetetrahydrofolate reductase, Correlation with homocystein metabolism and late-onset vascular disease", CIRCULATION, vol. 94, 1996, pages 3074 - 3078
- HOL F.A. ET AL: "Molecular genetic analysis of the gene encoding the trifunctional enzyme MTHFD in patients with neural tube defects", CLINICAL GENETICS, vol. 53, no. 2, February 1998 (1998-02-01), COPENHAGEN, DK, pages 119 - 125, XP008059705
- ROY ET AL: "Different Antifolate-resistant L1210 Cell Variants with either increased or decreased folylpolyglutamate synthase gene expression at the level of mRNA transcription", JOURNAL BIOLOGICAL CHEMISTRY, vol. 270, no. 45, 10 November 1995 (1995-11-10), pages 26918 - 26922
- MORAN R.G.: "Roles of folylpoly-gamma-glutamate synthase in therapeutics with tetrahydrofolate antimetabolites: an overview", SEMINARS IN ONCOLOGY, vol. 26, no. 2, SUPPL. 6, April 1999 (1999-04-01), W.B. SAUNDERS, US, pages 24 - 32, XP000857939
- SANGHANI P.C.; SANGHANI S.P.; MORAN R.G.: "Localization of the active site of recombinant human folylpoly-gamma-glutamate synthetase using active site labeling and site directed mutagenesis", FASEB JOURNAL, vol. 11, no. 9, August 1997 (1997-08-01), BETHESDA, MD, US, pages A1139, XP008073804

Cited by

CN112292730A

Designated contracting state (EPC)

AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE

DOCDB simple family (publication)

WO 0050639 A2 20000831; **WO 0050639 A3 20020510**; AU 3997300 A 20000914; CA 2362533 A1 20000831; EP 1224322 A2 20020724; JP 2003516111 A 20030513

DOCDB simple family (application)

US 0001392 W 20000120; AU 3997300 A 20000120; CA 2362533 A 20000120; EP 00919254 A 20000120; JP 2000601202 A 20000120